{
  "@context": "https://schema.org",
  "@graph": [
    {
      "@type": "Organization",
      "@id": "http://www.curonz.com/#organization",
      "name": "Curonz Limited",
      "url": "http://www.curonz.com/",
      "description": "Curonz Limited ☰ × home about research targets contact Curonz is a clinical stage Neurotherapeutics company with the vision to transform the Quality of Life of severely neurologically affected children and adult patients. Our approach involves a body and mind boosting drug therapy with a modified naturally occurring molecule named NRP2945 that controls seizure activity with simultaneous comorbidities improvement profiles in young patients diagnosed with epileptic encephalopathy syndromes like Lennox-Gastaut Syndrome and adults with drug resistant Temporal Lobe Epilepsy. NRP2945 exerts its activity via agonism of a novel CXCR4 receptor complex in an ultra-potent manner with no off-targe"
    },
    {
      "@type": "WebPage",
      "@id": "https://directory.websdocs.com/business/curonz-limited#asg",
      "name": "Curonz Limited ASG Directory Profile",
      "url": "https://directory.websdocs.com/business/curonz-limited",
      "isPartOf": {
        "@id": "http://www.curonz.com/#organization"
      },
      "description": "Public business information published by the WebsDocs ASG Directory."
    }
  ]
}